Regulatory approval
Published by the Health Canada. Approved
ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER positive, HER2-negative, PIK3CA Somatic variants | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| HC (1) | HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| HC (1) | ER positive, HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib |